Treatment with CUDC-907 resulted in a decrease in BAFFR and pre-BCR expression in splenic CD19+ leukemia cells, providing further support for our previous mechanistic study results at the cellular level (Fig. 6h). The gene discussed is BCR; the disease is leukemia.